CAR-T therapy for multiple myeloma in China. Does it make sense financially?

J Med Econ. 2023 Jan-Dec;26(1):824-825. doi: 10.1080/13696998.2023.2224636.
No abstract available

Publication types

  • Editorial

MeSH terms

  • China
  • Humans
  • Immunotherapy, Adoptive
  • Multiple Myeloma* / drug therapy
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell